News
Vantia Therapeutics announces £4 million fund raising
6 July 2011
Vantia Therapeutics raises £4 million to fund clinical development of lead compounds.
Vantia appoints new CEO
9 June 2010
Vantia Therapeutics announces that it has appointed Andrew Crockett to the position of Chief Executive Officer.
Vantia Therapeutics' Pipeline
Vantia's pipeline draws on the Company's world-recognised expertise in small molecule drug development. Its drug discovery engine is based on the Ferring Research Ltd small molecule R&D unit, which was spun out from Ferring Pharmaceuticals in 2008. Focussed on first-in-class therapies for indications that are under-served by current products, Vantia's R&D group has over 20 years' experience in the development of small molecule modulators targeting hormones and proteases.
The Company owns an extensive drug candidate library, which is driving its clinical and preclinical portfolio, and intellectual property comprising 20 patent families and 21 granted patents.
The current status of Vantia's pipeline is shown below - click on a compound name, or click the links under the "Pipeline" menu on the left, for more information.
| Platform | Compound | Indication(s) | MOA | Market Potential | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|---|
| GPCR | VA106483 | Nocturia | V2 Agonist | $1bn |  |
|
 |
|
| GPCR | VA111913 | Dysmenorrhoea | V1a Antagonist | $1-3bn | |
|
|
|
| Tissue Kallikrein | VA118020 | Severe Asthma | KLK1 Inhibitor | $3-7bn | |
|||
| Tissue Kallikrein | multiple | Inflammatory | KLK1 Inhibitor | TBA | |
|||
| FAP Inhibitor | VA999260 | Oncology/ Fibrosis | FAP Inhibitor | TBA | |
|||
| FAP Inhibitor | multiple | Oncology/ Fibrosis | FAP Inhibitor | TBA | |
